Audrey Bergan

Audrey Bergan joined ImmunoGen in 2014, bringing more than 20 years of experience in human resources and talent acquisition strategy. Responsible for leading ImmunoGen’s Human Resources team, she has been instrumental in defining and evolving the company’s culture and HR infrastructure. Prior to her current leadership role, Mrs. Bergan was responsible for building a Talent Acquisition function at ImmunoGen. Prior to ImmunoGen, she spent seven years at Biogen where she held multiple talent acquisition leadership roles. Mrs. Bergan holds a MS in Human Resourcing from Northeastern University, and a BS in Psychology from UMASS Amherst.

Anna Berkenblit, MD, MMsC

Dr. Berkenblit joined ImmunoGen in 2015 and is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates. She has extensive experience in the clinical development of novel anticancer therapies, including five years heading clinical research at two oncology-focused companies. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer compounds founded by Eisai Pharmaceuticals. Prior to H3 Biomedicine, she was VP, Head of Clinical Research at AVEO Oncology, where she led the clinical development of oncology product candidates spanning early testing to registration trials.

Prior to AVEO, Dr. Berkenblit held positions of increasing responsibility at
Wyeth and then Pfizer, becoming Vice President, Neratinib Asset Team Leader in the Pfizer Oncology Business Unit. Dr. Berkenblit earned an MD degree from Harvard Medical School, and an MMSc degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences & Technology. She completed her internship and residency at Brigham and Women’s Hospital, then went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center where she stayed on staff to focus on clinical research in GYN and GI malignancies. She also led the Phase I oncology clinical trial program as part of the Dana-Farber/Harvard Cancer Center, prior to transitioning to industry. Dr. Berkenblit currently serves on the Board of Directors of Surrozen, Inc.

DANIEL CHAR, JD

Mr. Char joined ImmunoGen in November 2022 from Evelo Biosciences where he served as General Counsel and Secretary providing strategic counsel and operational support on a broad range of business and legal issues, including business development, commercialization, healthcare fraud, and intellectual property. Prior to joining Evelo, Mr. Char was Associate General Counsel and Assistant Secretary at Smith+Nephew, after having served as General Counsel and Secretary at Targanta Therapeutics, Senior Associate General Counsel at Idenix Pharmaceuticals, and Associate General Counsel at Biogen. Mr. Char holds a JD from Harvard Law School and a BA in Economics from Tufts University.

Stacy Coen

Ms. Coen joined ImmunoGen in June 2020 from Editas Medicine, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions, and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntington’s Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.

Mark Enyedy

Mr. Enyedy joined ImmunoGen in 2016 as President and CEO, bringing over twenty-five years of combined general management, business development and legal experience in the biotechnology industry. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the Boston law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Ergomed plc, The American Cancer Society of Eastern New England, and the Biotechnology Innovation Organization. He previously served on the Board of Directors of LogicBio Therapeutics, Inc., Akebia Therapeutics, Inc., Fate Therapeutics, Inc., and Keryx Biopharmaceuticals, Inc.

ROBERT HERBST, PHD

Dr. Herbst joined ImmunoGen in 2010 and has held a variety of roles with increasing responsibility, including leading manufacturing sciences, process and analytical development (small molecule, biologics, and antibody-drug conjugates), manufacturing, and supply chain. Additionally, he served as CMC lead for internal programs and technical lead for partnered programs. Dr. Herbst received his BS in chemistry from Union College, a PhD in Bioinorganic Chemistry from the University of Massachusetts, Amherst, and completed post-doctoral training at Boston University.

ISABEL KALOFONOS

Ms. Kalofonos joined ImmunoGen in April 2023 from Galderma, where she served as Senior Vice President and Global Head of the Prescription Business Unit. During her tenure, she led the launch preparation for nemolizumab, a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, as well as global market access, real-world evidence, pricing, and health economics and outcomes research. She also led all commercial franchises of prescription products. Prior to Galderma, Ms. Kalofonos held roles of increasing responsibility at Takeda Pharmaceuticals (formerly Shire), most recently serving as Vice President and Head of the Hereditary Angioedema (HAE) franchise – a 2.5 billion dollar business. In this role she oversaw the global blockbuster launch of TAKHZYRO^® (lanadelumab-flyo). Prior to the Takeda acquisition, Ms. Kalofonos held roles of increasing responsibility at Shire within corporate strategy, new product planning, and commercial, and gained experience across multiple therapeutic areas including immunology, rare diseases, oncology, neurology, transplant, and gene therapy. Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals. Ms. Kalofonos received a BS from Pontificia Universidad Javeriana and an MBA from Babson College.

Renee Lentini

Ms. Lentini has served as ImmunoGen’s Vice President of Finance and Chief Accounting Officer since January 2021. She joined ImmunoGen in 2004 and has held various financial reporting and accounting positions of increasing responsibility, including oversight for global accounting, tax, and treasury. Ms. Lentini received her MS in Accounting from Stonehill College.

MASSIMO RADAELLI

Mr. Radaelli joined ImmunoGen in June 2022 to grow ImmunoGen’s business operations outside of the US and brings a wealth of expertise to the Company, with deep experience building biotech companies and bringing innovative medicines to patients worldwide. He previously served as Founder and Chairman of Pint Pharma, a specialty pharmaceutical company in Europe and Latin America, President and CEO of Dompé International, a European Biopharma company focused on oncology and rare diseases, founder of Dupont Merck in Italy, and held senior roles at Hoffman La Roche (Europe). Mr. Radaelli holds a degree in Pharmaceutical Science and a PhD in Clinical Pharmacology from the University of Milan as well as an Executive Masters Program from SDA Bocconi University of Milan.

Mike Vasconcelles, MD

Dr. Vasconcelles joined ImmunoGen in 2023 from Frazier Healthcare Partners where he served as a Senior Advisor to the Life Sciences team. Prior to that, he was the Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron Health, a health tech company focused on accelerating cancer research and improving patient care. Before joining Flatiron, Dr. Vasconcelles served as Chief Medical Officer at Unum Therapeutics, a cell and gene therapy company developing autologous engineered T-cell products for the treatment of cancer. He also spent several years at Takeda/Millennium, where he was Senior Vice President and Head of the Oncology Therapy Area Unit. Earlier in his career, Dr. Vasconcelles was Group Vice President and the Global Therapeutic Area Head of Transplant and Oncology at Genzyme Corporation, where he was responsible for clinical development of the transplant and oncology portfolio and a member of the Transplant and Oncology Business Unit management team. Following Sanofi’s acquisition of Genzyme, he joined Sanofi Oncology as Head of Personalized Medicine and Companion Diagnostics. Dr. Vasconcelles serves as a non-executive director of Molecular Partners AG and Magenta Therapeutics, Inc., a Board member of the Personalized Medicine Coalition and the Eastern New England American Cancer Society, and a member of several Scientific Advisory Boards within the biopharmaceutical industry. From 1996-2021, he was a faculty member at Harvard Medical School and an associate physician at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Dr. Vasconcelles received both his BA and MD from Northwestern University.

Theresa Wingrove, PhD

Dr. Wingrove joined ImmunoGen in early 2011 with over twenty years of regulatory and clinical management experience in the healthcare industry. Before joining ImmunoGen, she was the vice president of regulatory and clinical affairs at Histogenics, where her responsibilities included authoring and gaining approval of a SPA for a Phase III trial for a novel biologic and other regulatory responsibilities in the US and Europe. Prior to that, she was the senior director of regulatory and clinical affairs at MediSpectra, where she was responsible for the full spectrum of regulatory support – from start of clinical testing through marketing approval – for a novel cancer diagnostic product. Prior to joining MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten years, during which time she executed the clinical and regulatory programs associated with the company’s combination products. She holds a BS in Biochemistry from Brown University and a doctorate in Biochemical Toxicology from the University of Rochester.